Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimodivir (JNJ-63623872) Pre Approval Access_Single Patient Access (SPR) for Patients Diagnosed With H7N9 Influenza A Infection

Next Previous
Trial Profile

Pimodivir (JNJ-63623872) Pre Approval Access_Single Patient Access (SPR) for Patients Diagnosed With H7N9 Influenza A Infection

Status: Discontinued
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimodivir (Primary)
  • Indications Influenza A virus H7N9 subtype
  • Focus Expanded access; Therapeutic Use
  • Sponsors Janssen Research & Development

Most Recent Events

  • 02 Sep 2020 According to a Janssen media release, company discontinued development of pimodivir for the treatment of influenza A infection. This decision is based on results from pre-planned interim analyses of the pimodivir phase III trial in hospitalized patients with influenza A. Pimodivir in combination with the standard of care (SOC) fails to demonstrate added benefit in hospitalized patients with influenza A compared to SOC treatment alone.
  • 02 Sep 2020 Status changed from recruiting to discontinued, according to a Janssen media release.
  • 15 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top